Abstract
BACKGROUND: Radiomics, which involves the conversion of digital images into high-dimensional data, has been used in oncological studies since 2012. We analyzed the publications that had been conducted on this subject using bibliometric and visual methods to expound the hotpots and future trends regarding radiomics in evaluating lymph node status in oncology. METHODS: Documents published between 2012 and 2023, updated to August 1, 2024, were searched using the Scopus database. VOSviewer, R Package, and Microsoft Excel were used for visualization. RESULTS: A total of 898 original articles and reviews written in English and be related to radiomics for evaluating lymph node status in oncology, published between 2015 and 2023, were retrieved. A significant increase in the number of publications was observed, with an annual growth rate of 100.77%. The publications predominantly originated from three countries, with China leading in the number of publications and citations. Fudan University was the most contributing affiliation, followed by Sun Yat-sen University and Southern Medical University, all of which were from China. Tian J. from the Chinese Academy of Sciences contributed the most within 5885 authors. In addition, Frontiers in Oncology had the most publications and transcended other journals in recent 4 years. Moreover, the keywords co-occurrence suggested that the interplay of "radiomics" and "lymph node metastasis," as well as "major clinical study" were the predominant topics, furthermore, the focused topics shifted from revealing the diagnosis of cancers to exploring the deep learning-based prediction of lymph node metastasis, suggesting the combination of artificial intelligence research would develop in the future. CONCLUSION: The present bibliometric and visual analysis described an approximately continuous trend of increasing publications related to radiomics in evaluating lymph node status in oncology and revealed that it could serve as an efficient tool for personalized diagnosis and treatment guidance in clinical patients, and combined artificial intelligence should be further considered in the future.